supported by following fundings:the National Key R&D Program of China(No.2022YFC3601800);the CAMS Innovation Fund for Medical Sciences(No.2021-I2M-1-059);non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences(No.2021-RC320-001,No.2020-RC320-003);the Special Program of National Natural Science Foundation of China(NO.32141004);the Special Research Fund for Central Universities,Peking Union Medical College(No.3332023075);Natural Science Foundation of Jiangsu Province(No.BK20230130);National Natural Science Foundation of China(No.82302982).
Current therapies for systemic lupus erythematosus that target a particular factor or cell type exhibit limited effectiveness.To address this limitation,our focus was on CD132,a subunit common to six inflammatory fact...